Chee Hong Takahiro Yew

Mr. Chee Hong Takahiro Yew

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2018 in Polymers
Verified
Journal Article
Open access
PDF file
CYChee Hong Takahiro Yew
Chee Hong Takahiro Yew
PAPedram Azari
Pedram Azari
JCJane Ru Choi
Jane Ru Choi
FMFarina Muhamad
Farina Muhamad
BMBelinda Pingguan Murphy
Belinda Pingguan Murphy
Electrospun polycaprolactone (PCL) nanofibers have emerged as a promising material in diverse biomedical applications due to their various favorable features. However, their application in the field of biosensors such as point-of-care lateral flow assays (LFA) has not been investigated. The present study demonstrates the use of electrospun PCL nanofibers as a reaction membrane for LFA. Electrospun PCL nanofibers were treated with NaOH solution for different concentrations and durations to achieve a desirable flow rate and optimum detection sensitivity in nucleic acid-based LFA. It was observed that the concentration of NaOH does not affect the physical properties of nanofibers, including average fiber diameter, average pore size and porosity. However, interestingly, a significant reduction of the water contact angle was observed due to the generation of hydroxyl and carboxyl groups on the nanofibers, which increased their hydrophilicity. The optimally treated nanofibers were able to detect synthetic Zika viral DNA (as a model analyte) sensitively with a detection limit of 0.5 nM. Collectively, the benefits such as low-cost of fabrication, ease of modification, porous nanofibrous structures and tunability of flow rate make PCL nanofibers a versatile alternative to nitrocellulose membrane in LFA applications. This material offers tremendous potential for a broad range of point-of-care applications.

1 June 2018 in Analytica Chimica Acta
Verified
Journal Article
Closed access
CYChee Hong Takahiro Yew
Chee Hong Takahiro Yew
PAPedram Azari
Pedram Azari
JCJane Ru Choi
Jane Ru Choi
FLFei Li
Fei Li
BMBelinda Pingguan Murphy
Belinda Pingguan Murphy

1 October 2026 in NAR Molecular Medicine
Verified
Journal Article
Open access
AMArthur Millius
Arthur Millius
CYChee Hong Takahiro Yew
Chee Hong Takahiro Yew
YMYuko Misumi
Yuko Misumi
JYJian Yu
Jian Yu
DTDaisuke Takaya
Daisuke Takaya
DSDaron Standley
Daron Standley
Regnase-1 is an essential RNase that suppresses immune cell activation by targeting the mRNA of pro-inflammatory cytokines such as interleukin 6 (IL-6). Although genetic inhibition of Regnase-1 activity in CD8+ T cells has been shown to enhance antitumor immunity, no molecular inhibitors of Regnase-1 have been reported. By exploiting a library of nucleic acid analogs in conjunction with an RNA displacement assay, we identified multiple candidate competitors of Regnase-1 RNA substrates. Among these, suramin—an approved drug for treating African sleeping sickness—and several of its derivatives displaced Regnase-1 RNA targets with submicromolar affinity, competitively inhibited Regnase-1–mediated degradation of RNA in vitro, and enhanced Il6 mRNA levels and IL-6 production in mouse embryonic fibroblasts. A 2.62 Å crystal structure revealed that suramin bound to the Regnase-1 active site, coordinating with the catalytic Mg2+. Quantum chemical calculations further elucidated qualitative interactions between suramin and surrounding residues of Regnase-1. These findings establish suramin as a small-molecule inhibitor of Regnase-1–mediated RNA decay.